IntroductionSepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to increase global awareness, standardize patient care, and reduce levels of mortality for sepsis. Negative clinical trial data have dented the commercial performance of Eli Lilly's Xigris, creating an opportunity for improved sepsis therapeutics.Features and benefits* Profile and clinical and commercial evaluation of Eli Lilly's Xigris (drotrecogin alfa [activated]).* Review of unmet needs for sepsis and future challenges and opportunities in sepsis diagnosis and treatment.* Overview of the Surviving Sepsis Campaign, including an evaluation of its impact on sepsis patient care.HighlightsEli Lilly's Xigris is currently the only marketed direct therapy for sepsis. However, its commercial performance has been disappointing, despite its market monopoly, due to negative results from clinical trials conducted post-approval. Upcoming results from the PROWESS-SHOCK trial are likely to be critical to the future success of the drug.There is a high unmet need for the identification and utilization of sepsis biomarkers that can identify those patients who would most likely benefit from new drugs and monitor patient response to therapies. However, current approaches lack the required predictive capability and reliability to be employed in clinical practice.The Surviving Sepsis Campaign (SSC) has proved successful in increasing global awareness of sepsis, standardizing patient care, and reducing patient mortality rates. However, the development of the SSC guidelines has been associated with controversy due to links with industry (particularly Eli Lilly).Your key questions answered* Understand the commercial and clinical attractiveness of Eli Lilly's Xigris and the key reasons behind its disappointing commercial performance.* Understand key unmet needs in sepsis and potential future developments in diagnosis and therapy.* Gain insight into the Surviving Sepsis Campaign and its impact on sepsis management.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Case Study: Sepsis - Xigris' disappointing performance creates a
market opportunity for improved sepsis therapies
Published on May 2011
Report Summary
Introduction
Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to
increase global awareness, standardize patient care, and reduce levels of mortality for sepsis. Negative clinical trial data have dented
the commercial performance of Eli Lilly's Xigris, creating an opportunity for improved sepsis therapeutics.
Features and benefits
* Profile and clinical and commercial evaluation of Eli Lilly's Xigris (drotrecogin alfa [activated]).
* Review of unmet needs for sepsis and future challenges and opportunities in sepsis diagnosis and treatment.
* Overview of the Surviving Sepsis Campaign, including an evaluation of its impact on sepsis patient care.
Highlights
Eli Lilly's Xigris is currently the only marketed direct therapy for sepsis. However, its commercial performance has been disappointing,
despite its market monopoly, due to negative results from clinical trials conducted post-approval. Upcoming results from the
PROWESS-SHOCK trial are likely to be critical to the future success of the drug.
There is a high unmet need for the identification and utilization of sepsis biomarkers that can identify those patients who would most
likely benefit from new drugs and monitor patient response to therapies. However, current approaches lack the required predictive
capability and reliability to be employed in clinical practice.
The Surviving Sepsis Campaign (SSC) has proved successful in increasing global awareness of sepsis, standardizing patient care,
and reducing patient mortality rates. However, the development of the SSC guidelines has been associated with controversy due to
links with industry (particularly Eli Lilly).
Your key questions answered
* Understand the commercial and clinical attractiveness of Eli Lilly's Xigris and the key reasons behind its disappointing commercial
performance.
* Understand key unmet needs in sepsis and potential future developments in diagnosis and therapy.
* Gain insight into the Surviving Sepsis Campaign and its impact on sepsis management.
Table of Content
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Case Study: Sepsis - Xigris' disappointing performance creates a market opportunity for improved sepsis therapies (From Slideshare) Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Related reports
OVERVIEW
Catalyst
Summary
TREATMENT GUIDELINES
The SSC guidelines aim to translate evidence-based patient management recommendations into clinical practice
The Surviving Sepsis Campaign
Upon initiation, the key aim of the SSC was to drive a significant reduction in mortality from severe sepsis and septic shock
The SSC has had a positive impact on standardizing and guiding sepsis patient care and reducing levels of mortality
Sources of funding, incorporation of Xigris in the SSC guidelines, and committee members' links to Eli Lilly are among questions
raised over the influence of industry on the SSC
PRODUCT PROFILE: XIGRIS
Drug profile
Historic sales overview
A restricted label and unfavorable clinical trial data have harmed the revenue potential of Xigris
Development overview
Clinical trial results for Xigris released since its launch have proved harmful to its commercial performance
SWOT analysis
A range of clinical weaknesses will continue to harm the commercial prospects for Xigris, despite large markets and significant
opportunities for the drug
Product positioning
Reduction in mortality in critically ill patients is the key brand message for Xigris
Physician perception of Xigris
Despite its well-publicised drawbacks, physicians recognize that Xigris is an efficacious drug in the patient group for which it is
indicated
Clinical and commercial attractiveness
A restricted label and safety issues limit the market opportunity for sepsis, despite a large potential patient population
The strong sales and marketing capabilities of Eli Lilly and a clear brand message have been unable to significantly lift sales of
Xigris
UNMET NEEDS
With just one marketed therapy, there is a strong unmet need for new efficacious and safe sepsis drugs and therapeutic approaches
Improvements in clinical trial design would facilitate a more accurate evaluation of new sepsis drugs
Biomarkers may play a crucial future role in sepsis diagnosis and treatment, although substantial challenges remain before they can
be integrated into clinical practice
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX A
Data definitions, limitations, and assumptions
Exchange rates
APPENDIX B
Contributing experts
Conferences attended
Report methodology
Case Study: Sepsis - Xigris' disappointing performance creates a market opportunity for improved sepsis therapies (From Slideshare) Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Case Study: Sepsis - Xigris' disappointing performance creates a market opportunity for improved sepsis therap
ies
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 900.00 Quantity: _____
Corporate License--USD 4 750.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Case Study: Sepsis - Xigris' disappointing performance creates a market opportunity for improved sepsis therapies (From Slideshare) Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Case Study: Sepsis - Xigris' disappointing performance creates a market opportunity for improved sepsis therapies (From Slideshare) Page 4/4